Developing new psychedelic compounds

Developing new psychedelic compounds presents both opportunities and challenges. On one hand, it allows for the improvement of the attributes of psychedelics in terms of safety and effectiveness in therapeutic settings. This includes making them faster acting or designing a smoother onset of the experience. On the other hand, making tweaks to first-generation psychedelics before they are FDA approved raises questions of whether it is getting ahead of the process. Tactogen, a drug development company, aims to create new chemical entities inspired by MDMA that are gentler and safer, with potential for administration in an at-home setting.